Sara A. Hurvitz
The University of Texas MD Anderson Cancer Center(US)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Breast Cancer Treatment Studies, Lung Cancer Research Studies
Most-Cited Works
- → Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation(2018)2,082 cited
- → Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer(2019)1,885 cited
- → Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer(2021)1,447 cited
- → ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer(2021)1,287 cited
- → Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer(2019)1,275 cited
- → Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer(2019)1,001 cited
- → Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial(2018)986 cited
- → Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology(2022)945 cited
- → Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial(2022)595 cited
- → Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial(2020)594 cited